ChengZLiuMD

Anatomic Pathology, Clinical Pathology

Professor, Department of Pathology, New York University School of Medicine

Dr. Liu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Cheng Z. Liu is a pathologist in New York, NY at NYU Langone Hospitals. He received his medical degree from Hubei Medical University and has been in practice 25 years. He specializes in anatomic pathology and clinical pathology.

The MetroHealth System/Case Western Reserve UniversityResidency, Pathology-Anatomic and Clinical, 1996 - 2000
Northwestern university Ph.D., Cell and Molecular Pathology , 1990 - 1995
Hubei Medical UniversityClass of 1982

PubMed

20 citations
Cathepsin S Evokes PAR2-Dependent Pain in Oral Squamous Cell Carcinoma Patients and Preclinical Mouse Models.
Nguyen Huu Tu, Kenji Inoue, Elyssa Chen, Bethany M. Anderson, Caroline M. Sawicki
Cancers. 2021-09-19
33 citations
Legumain Induces Oral Cancer Pain by Biased Agonism of Protease-Activated Receptor-2.
Nguyen Huu Tu, Dane D. Jensen, Bethany M. Anderson, Elyssa Chen, Nestor N. Jiménez-Vargas
The Journal of Neuroscience. 2021-01-06
17 citations
Oral cancer induced TRPV1 sensitization is mediated by PARsignaling in primary afferent neurons innervating the cancer microenvironment.
Nicole N Scheff, Ian M Wall, Sam Nicholson, Hannah Williams, Elyssa Chen
Scientific Reports. 2022-03-08

Eureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment of Multiple MyelomaSeptember 28th, 2022
Eureka Therapeutics Announces Publication of Crystal Structure of TCR Mimic Redirected T Cells Targeting Alpha-Fetoprotein (AFP) for Liver CancerAugust 3rd, 2022
Eureka Therapeutics Announces Publication of Study Demonstrating Broad Anti-Tumor Activity of TCR Mimic-Redirected T Cells Targeting NDC80June 6th, 2022
Join now to see all